Five years without metastasis often means years without chemotherapy, without bone pain.
Apalutamida associada à ADT alcançou resposta patológica completa em 5,1% vs 0,4% com placebo, com redução de margens cirúrgicas positivas de 42,7% para 20,9%. Sobrevida livre de metástases em 5 anos foi 78,2% com apalutamida versus 73,5% com placebo, representando benefício clínico significativo em população de alto risco.
- 2,109 men enrolled between July 2019 and June 2022; 95.8% had Gleason score ≥8
- Complete pathological response: 5.1% with apalutamide vs 0.4% with placebo
- Five-year metastasis-free survival: 78.2% vs 73.5% (20% risk reduction)
- Skin rash in 21.2% of apalutamide group vs 10% of placebo; caused 7.4% discontinuation
- Fatal adverse events: 1.3% with apalutamide vs 0.5% with placebo during treatment
Estudo PROTEUS apresenta resultados positivos da apalutamida combinada com deprivação androgênica no tratamento perioperatório do câncer de próstata localizado de alto risco, reduzindo risco de metástases em 20%.
The American Society of Clinical Oncology's 2026 annual meeting opened with results that could reshape how doctors treat men with aggressive, localized prostate cancer. The PROTEUS trial, presented on the second day of the conference, tested whether adding apalutamide—an oral hormone-blocking drug—to standard androgen deprivation therapy before and after surgery could prevent the cancer from spreading.
Between 2019 and 2022, researchers enrolled 2,109 men with newly diagnosed, high-risk prostate cancer who were candidates for surgical removal of the prostate and pelvic lymph nodes. Half received apalutamide at 240 milligrams daily combined with hormone therapy; the other half received the same hormone therapy with a placebo. Both groups took their assigned treatment for six cycles of 28 days before surgery and six cycles after—roughly a year of perioperative care. The men in the study were genuinely sick: 95.8 percent had aggressive Gleason scores of 8 or higher, more than a third had locally advanced tumors, and one in eight had cancer in their lymph nodes at diagnosis.
The drug worked. Among men receiving apalutamide, 5.1 percent achieved a complete pathological response—meaning no cancer cells remained in the surgical specimen—compared to just 0.4 percent in the placebo group. Positive surgical margins, a sign the surgeon couldn't fully remove the cancer, dropped from 42.7 percent down to 20.9 percent. These are the kinds of immediate, measurable improvements that oncologists watch closely.
But the headline number was metastasis-free survival. After five years, 78.2 percent of men on apalutamide remained free of distant cancer spread, versus 73.5 percent in the placebo group. That 4.7 percentage point difference translates to a 20 percent reduction in the risk of metastasis. The median time to any subsequent treatment—whether local radiation or systemic chemotherapy—stretched to 74.2 months with apalutamide, nearly double the 41.5 months in the control arm. These are not trivial gains in a disease where half of untreated high-risk patients relapse within five years.
The safety profile, however, demands attention. Nearly all men in both groups experienced some side effect, but the apalutamide arm saw more severe toxicity: 39.6 percent experienced grade 3 or 4 adverse events compared to 31 percent on placebo. Hot flashes, urinary incontinence, erectile dysfunction, fatigue, joint pain, and skin rash were common. The rash emerged as the signature toxicity of apalutamide, appearing in 21.2 percent of treated men versus 10 percent on placebo. This difference drove treatment discontinuation in 7.4 percent of the apalutamide group—more than double the 2.7 percent who stopped placebo. During the treatment period itself, fatal adverse events occurred in 1.3 percent of men on apalutamide and 0.5 percent on placebo.
The trial's strength lies in its scale and rigor: a randomized, double-blind, placebo-controlled phase 3 study with median follow-up exceeding five years. Its limitation is equally important. The control arm—men receiving only hormone therapy without an oral antiandrogen—does not reflect standard clinical practice. Many of these high-risk patients would ordinarily receive extended hormone blockade after surgery, often combined with an oral antiandrogen anyway. This raises a fair question: how much of the benefit comes from apalutamide itself, and how much from the intensity of the overall hormonal strategy? Overall survival data remain immature, meaning we don't yet know whether preventing metastases translates into living longer. That answer will arrive in time, but for now, PROTEUS offers a meaningful tool for men facing the worst forms of localized prostate cancer—one that demands careful monitoring for skin toxicity but delivers measurable protection against the spread that kills.
Notable Quotes
PROTEUS demonstrates a strategy with impact on metastasis-free survival, maintaining efficacy with an adverse event profile compatible with clinical practice.— Trial commentary
Perioperative androgen deprivation therapy is not standard clinical practice; many of these patients would ordinarily receive extended androgen blockade adjuvantly, possibly combined with an oral antiandrogen.— Trial commentary
The Hearth Conversation Another angle on the story
Why does a 4.7 percentage point difference in five-year metastasis-free survival matter so much in a disease where half the men relapse anyway?
Because in high-risk prostate cancer, five years without metastasis often means five years of life without chemotherapy, without bone pain, without the cascade of treatments that follow spread. For a man in his sixties or seventies, that's not abstract—it's years of relative normalcy.
But the rash sent 7.4 percent of men off the drug entirely. Doesn't that undercut the benefit?
It does, and it's honest to say so. You're trading one problem—the risk of metastasis—for another: a skin condition severe enough that some men choose to stop. The question becomes whether the men who tolerate it gain enough to justify the ones who don't.
The control arm bothers me. You said it's not standard practice. So what are we really measuring?
We're measuring apalutamide plus hormone therapy against hormone therapy alone. But in the real world, many of these men would get hormone therapy plus something else—maybe a different antiandrogen, maybe radiation. The trial doesn't tell us whether apalutamide is better than those alternatives, only that it's better than nothing extra.
Overall survival is still immature. How long until we know if this actually helps men live longer?
That's the honest answer nobody has yet. Metastasis-free survival is a proxy—a reasonable one, but still a proxy. The trial will keep following these men, but we're probably years away from knowing whether preventing spread translates into extra years of life.
For a man diagnosed tomorrow with high-risk prostate cancer, what does PROTEUS actually change?
It gives his surgeon and oncologist a new option to discuss. It's not a mandate—it's evidence that adding apalutamide to the standard approach improves the odds of staying metastasis-free. Whether he takes it depends on how much he fears that rash, how much he values those extra years without spread, and what his doctors think about the control arm critique.